Cargando…

Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes

The major trials, e.g., EMPA-REG OUTCOME, CANVAS, and CREDENCE, showed the renal and cardiovascular benefit of sodium-glucose transport protein 2 (SGLT2) inhibitors. The SGLT2 inhibitors, Empagliflozin, Dapagliflozin, and Canagliflozin, have shown no significant adverse renal effects. Still, our pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Rajesh, Bhavatharini, Natrajan, Saravanan, Thangavel, Seshiah, Veeraswamy, Jain, Nishchal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Endocrinology/Diabetes/Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840745/ https://www.ncbi.nlm.nih.gov/pubmed/36654590 http://dx.doi.org/10.7759/cureus.32573

Ejemplares similares

Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Case Report and Review of Literature
por: Aggarwal, Ankita, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Transgenerational Transmission of Non-communicable Diseases: How to Break the Vicious Cycle?
por: Bronson, Stephen C, et al.
Publicado: (2021)

Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
por: Maradia, Jay, et al.
Publicado: (2023)

A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Patel, Khyati, et al.
Publicado: (2022)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
por: Donnan, Jennifer R, et al.
Publicado: (2019)

The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
por: Shami, Dalia, et al.
Publicado: (2023)

Diagnosing Gestational Diabetes by a Single-Test Procedure Is a Propitious Step Towards Containing the Epidemic of Diabetes
por: Seshiah, V, et al.
Publicado: (2021)

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis
por: Xu, Lubin, et al.
Publicado: (2017)

LBODP041 Effects Of Sodium-glucose Co-transporter 2 Inhibitors (sglt-2 Inhibitors) On Adipokines And Inflammatory Biomarkers In Type2 Diabetic Patients
por: Kumtree, Phonphruet
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers
por: Somagutta, Manoj R, et al.
Publicado: (2021)

Clinical And Biochemical Outcomes Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors In Type 2 Diabetes Mellitus Patients
por: Saleem, Muhammad, et al.
Publicado: (2021)

Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
por: Fatima, Tehreem, et al.
Publicado: (2020)

Prediction and Prevention of Gestational Diabetes Mellitus and Its Sequelae by Administering Metformin in the Early Weeks of Pregnancy
por: Seshiah, V, et al.
Publicado: (2022)

Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy
por: Chowdhury, Tutul, et al.
Publicado: (2022)

Sodium Glucose Co-Transporter2 (SGLT2) Inhibition for Refractory Hypomagnesemia in Monogenic Diabetes Type 5 (MODY 5)
por: Paul, Anju A, et al.
Publicado: (2021)

A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors
por: Chaurasia, Pallavi Prakash, et al.
Publicado: (2021)

Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control
por: Onyali, Chike B, et al.
Publicado: (2021)

Differential effect of canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice
por: Otsuka, Hiroko, et al.
Publicado: (2022)

Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
por: Hussain, Mazhar, et al.
Publicado: (2021)

Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Bariatric Surgery: A Case and Literature Review
por: Kapila, Vaishali, et al.
Publicado: (2021)

Sodium-glucose Cotransporter-2 Inhibitors and Euglycaemic Diabetic Ketoacidosis in the Perioperative Period: Case Report
por: Jhaveri, Urmita, et al.
Publicado: (2019)

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
por: Simões de Carvalho, Francisco, et al.
Publicado: (2023)

Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor
por: Sugiyama, Seigo, et al.
Publicado: (2020)

Postoperative Euglycemic Ketoacidosis in Type 2 Diabetes Associated with Sodium-Glucose Cotransporter 2 Inhibitor: Insights Into Pathogenesis and Management Strategy
por: Chandrakumar, Harshith P, et al.
Publicado: (2021)

SUN-LB112 Efficacy & Safety After Switchover to Remogliflozin in Indian T2DM Patients - a Real World Study
por: Bhattacharyya, Supratik, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Followed by Excessively Low Carbohydrate Diet
por: Tsutsui, Erika, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature
por: Gajjar, Kushani, et al.
Publicado: (2019)

Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 Inhibitor Use and Recent Sleeve Gastrectomy
por: Smith, Alexander, et al.
Publicado: (2021)

Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia
por: Somaili, Mohammed, et al.
Publicado: (2022)

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
por: Kapur, Anita, et al.
Publicado: (2013)

Euglycemic Diabetic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor Use Post-Bariatric Surgery: A Brief Review of the Literature
por: Iqbal, Qasim Z, et al.
Publicado: (2020)

Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation
por: Tauseef, Abubakar, et al.
Publicado: (2020)

Hypertriglyceridemia-Induced Acute Pancreatitis, Euglycemic Diabetic Ketoacidosis and COVID-19 Infection in a Patient With Type 2 Diabetes Taking a Sodium-Glucose Cotransporter 2 Inhibitor
por: Acevedo-Mendez, Bernardo A, et al.
Publicado: (2021)

Continuous Glucose Monitoring Versus Self-monitoring of Blood Glucose in Type 2 Diabetes Mellitus: A Systematic Review with Meta-analysis
por: Janapala, Rajesh Naidu, et al.
Publicado: (2019)

THU291 Successful Reversal Of Glucose Toxicity After DKA Precipitated By SGLT2 Inhibitor
por: Abdelrahman, Houda, et al.
Publicado: (2023)

Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review
por: Elshimy, Ghada, et al.
Publicado: (2019)

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol
por: Hussein, Humaira, et al.
Publicado: (2018)

FRI648 GLP-1RA And SGLT2i Treatments May Show Improved Depression Metrics In Diabetes Treatment
por: Jain, Arad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a83vkfau0tnl7pgm2rc5jll7rs